Announced Thu, 22 Oct, 2026 · 15:15 IST
Board to approve Q2 FY2027 unaudited results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reactionminutes from the announcement price · days from the prior close
-1.9%Reaction day
₹29.62
prior close
₹29.29
announcement price
In-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used-1.0%-0.9% vs market
Pharmaceuticals peers, median of 170sector-0.5%-1.4% vs sector
On the reaction day the stock moved 0.9 pts less than Nifty Microcap 250 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
—
10m
—
15m
—
30m
—
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.9-1.0-0.9-0.5-1.4
Next day
-6.8-3.3-3.5-2.2-4.7
2d
-11.4-2.9-8.5-1.1-10.4
3d
-12.2-1.3-10.9+0.7-12.9
4d
-8.9pendingpending+1.9-10.8
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 170Pending
Minute windows have no benchmark: there is no intraday index history to compare against.
AI summary
The Board will meet on 5 November 2026 at 1:45 p.m. to approve unaudited results for the half year and quarter ended 30 September 2026. No financial figures or auditor changes are disclosed.
Likely market impact
The meeting date may cause short-term market volatility, but no earnings figures are provided to assess performance.